Mckinsey and Company

JANUARY 11, 2023

In the wake of the COVID-19 pandemic, one of the first non-French leaders of the pharmaceutical company Sanofi explains cultural transformations, the growth of AI in decision making, and how he stays humble.

75

75

Benzinga

DECEMBER 2, 2022

Sanofi (NASDAQ: SNY ) said that if it ever bid for biotech company Horizon Therapeutics Public Limited Co (NASDAQ: HZNP ), it would do so in cash.

Market Capitalization 52

Market Capitalization Marketability 52

Benzinga

APRIL 1, 2022

Sanofi SA (NASDAQ: SNY ) plans to list its drug ingredients subsidiary EUROAPI on May 6 , saying the business is set to grow and improve its profitability as a separate business. Sanofi shareholders will receive one EUROAPI share for 23 shares held in the parent company. The company confirmed plans to conserve a.

52

52

Benzinga

NOVEMBER 30, 2022

Horizon Therapeutics Plc (NASDAQ: HZNP ) confirmed it's engaged in preliminary talks with Amgen Inc (NASDAQ: AMGN ), Janssen Global Service , and Sanofi SA (NASDAQ: SNY ) on potential takeover offers for the company. According to a statement, there is no certainty that an offer for the company will be made.

Marketability 52

Marketability 52

Law 360 M&A

JUNE 2, 2022

Denner and the activist hedge fund he controlled must face insider trading claims in a Delaware Chancery Court lawsuit alleging an unfair deal process behind the company's $11.6 billion sale to Sanofi in 2018.

52

52

Law 360 M&A

MARCH 13, 2023

Sanofi SA, led by Weil Gotshal & Manges LLP, will acquire New Jersey-based pharmaceutical company Provention Bio Inc., billion in equity, according to an announcement by both companies Monday. advised by Ropes & Gray LLP, in a deal worth $2.9

Equity 40

Equity 40

Law 360 M&A

APRIL 17, 2023

will seek an up to $21 million award for their work brokering an $84 million deal to partially settle a class challenge in Delaware Chancery Court to the company's sale to Sanofi in 2018. Attorneys representing stockholders of Bioverativ Inc.

40

40

Law 360 M&A

APRIL 13, 2023

have settled for $84 million a Delaware Court of Chancery class challenge to the company's sale to Sanofi Inc. Stockholders of biotech venture Bioverativ Inc. in 2018, releasing most directors and officers while board member Alexander Denner and his hedge fund remain headed to trial.

40

40

Benzinga

NOVEMBER 30, 2022

Horizon Therapeutics Plc (NASDAQ: HZNP ) confirmed it's engaged in preliminary talks with Amgen Inc (NASDAQ: AMGN ), Janssen Global Service , and Sanofi SA SNY on potential takeover offers for the company. SVB Leerink projects 2023 revenue of $4.0 billion, adj operating income of $1.6 billion, and EPS of $5.51.

52

52

Law 360 M&A

DECEMBER 15, 2022

a hemophilia-focused biopharm that Sanofi SA bought in 2018, has sued both companies in Delaware Chancery Court, alleging they have refused to pay his legal fees in an ongoing shareholder suit accusing him of insider trading ahead of the $11.6 A former board member of Bioverativ Inc., billion merger.

40

40

Law 360 M&A

AUGUST 22, 2022

A California executive compensation expert told a Manhattan federal judge that he made illegal bets on a pharmaceutical sector client company that had been targeted for acquisition by global giant Sanofi SA, copping to insider trading charges.

40

40

Law 360 M&A

JULY 21, 2022

Denner decision, that Bioverativ directors may have breached their fiduciary duties when Sanofi purchased the company, expands the court's approach on director independence, severance-related conflicts and gaps in board minutes, say attorneys at Fried Frank. The Delaware Chancery's recent Goldstein v.

40

40

Law 360 M&A

APRIL 4, 2023

investor has filed a lawsuit seeking to delay the biopharmaceutical company's pending $2.9 A Provention Bio Inc.

Equity 40

Equity 40

John Jenkins

MAY 27, 2022

5/22), the Delaware Chancery Court refused to dismiss breach of fiduciary duty claims against the officers and directors of Bioverativ arising out of the company’s 2018 sale for Sanofi. This is another one of Vice Chancellor Laster’s 100+ page opinions, so there’s certainly a lot I could talk […]

40

40

Benzinga

AUGUST 30, 2022

Mergers and acquisitions are a growing trend among major companies across the world. Industry Developments: February 2019: Jubilant Biosys collaborated with Sanofi to develop small molecule inhibitors for in the CNS therapeutic area. Pune, India, Aug. billion by the end of 2026. billion in 2018 and will exhibit a CAGR of 10.0%

Marketability 40

Marketability 40

Benzinga

SEPTEMBER 13, 2022

announced the company's plans for deploying mRNA technology for the development and manufacturing of influenza, HIV, and Nipah virus vaccines. Sanofi (France), AstraZeneca (U.K.), This information is cited by Fortune Business Insights™ in its research report titled, Influenza Vaccine Market, 2022-2029. Market Size in 2021.

Marketability 40

Marketability Technology 40

Cooley M&A

JANUARY 23, 2024

Strained access to public markets and funding The IPO market remained relatively inactive in 2023, leading many life sciences companies looking to raise funds to turn to other exit strategies. Others have pursued less-traditional acquisitions, choosing to instead form alliances and partnerships.

Marketability 52

Marketability Equity Private Equity Firm Finance 52

Reynolds Holding

APRIL 14, 2024

Typically, these cases involve a defendant who is an employee or agent of a company undertaking a takeover, and the defendant buys stock in the target of the takeover, using information that he learned from his client, the prospective bidder. Here, the two companies are linked in a transaction that is probably material to both.

Marketability 105

Marketability Banking 105

Benzinga

MAY 10, 2022

March 2021 - Sanofi announced its plan to invest around USD 736.9 The company aims to quadruple the supply of vaccines in the country, the U.S., Therefore, the increasing focus on the supply of vaccines by several International Health Organizations is likely to propel the demand for the products in the forthcoming years.

Marketability 40

Marketability 40

Benzinga

JANUARY 17, 2024

INVO (NASDAQ: INVO ) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024 Experienced, entrepreneurial leadership team to help structure merged public company and accelerate growth SARASOTA, Fla. Mark Rothera, MBA is an experienced commercial executive and serial public company CEO.

Marketability 40

Marketability Finance 40

Reynolds Holding

JANUARY 23, 2024

Kraft Heinz The $450 million settlement against Kraft Heinz arises out of the tumultuous merger in 2015 that created the company. A week after a New York Times article exposed some of the practices in July 2017, the company admitted in a SEC filing that it had been aware of the problems previously. billion in cost savings.

Banking 59

Banking Private Equity Firm Alpha Compliance 59

Harvard Corporate Governance

AUGUST 5, 2022

by Sanofi, S.A. The sale process was led by an outside director, “D,” an activist investor, who allegedly was acting in accordance with his “usual playbook” of pressuring a public company into putting him on the board, then recruiting his “supporters” onto the board, and then forcing a near-term sale of the company.

201

201

Cooley M&A

JANUARY 22, 2020

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 billion acquisition of The Medicines Company. billion; and Synthorx’s sale to Sanofi $2.5

Marketability 40

Marketability Technology 40

Benzinga

NOVEMBER 16, 2023

-- The combined company will operate as Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. -- The combined company will operate as Q32 Bio Inc., and BEDFORD, Mass., 16, 2023 (GLOBE NEWSWIRE) -- Q32 Bio Inc., and BEDFORD, Mass.,

Finance 45

Finance Technology 45

Reynolds Holding

OCTOBER 5, 2022

Lucia Companies, Inc. In Lee Enterprises , a beneficial owner of the company sought to nominate several directors as part of a takeover attempt, but it failed to comply with unambiguous advance notice bylaws requiring it to become a record holder and submit the company’s nominee questionnaire forms before the nomination deadline.

Start-ups 72

Start-ups Marketability Equity Compliance 72

Reynolds Holding

JANUARY 21, 2024

As we previously discussed, the new Merger Guidelines demonstrate an increased focus on vertical and conglomerate transactions, competition for labor, potential competition, transactions involving private equity and technology companies, and market trends toward concentration. Other notable changes include: Structural Presumptions.

Marketability 45

Marketability Technology Equity 45